TriangleElacestrant (NCT06923527)
Elacestrant trial for ER+ Breast Cancer (NCT06923527). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults previously treated for stage IIB or III, estrogen-receptor-positive, HER2-negative breast cancer, diagnosed 5–20 years ago. Treatment requires detectable tumor DNA in blood but no visible metastases.
The idea: daily oral elacestrant breaks down estrogen receptors. Researchers test whether it clears tumor DNA. Treatment lasts one year, with a possible second year. Pre/perimenopausal participants also need ovarian suppression.
This phase 2 study plans 50 patients. Yale’s Mariya Rozenblit leads it; six US sites are recruiting, including New Haven.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.